GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Transl Med
Hlavní autoři: Pietrantonio, Filippo, Berenato, Rosa, Maggi, Claudia, Caporale, Marta, Milione, Massimo, Perrone, Federica, Tamborini, Elena, Baratti, Dario, Kusamura, Shigeki, Mariani, Luigi, Niger, Monica, Mennitto, Alessia, Gloghini, Annunziata, Bossi, Ilaria, Settanni, Giulio, Busico, Adele, Bagnoli, Pietro Francesco, Di Bartolomeo, Maria, Deraco, Marcello, de Braud, Filippo
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/
https://ncbi.nlm.nih.gov/pubmed/27154293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky